Log in

Ra Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RARX)

$46.25
+0.01 (+0.02 %)
(As of 10/22/2019 06:03 AM ET)
Today's Range
$46.15
Now: $46.25
$46.49
50-Day Range
$22.90
MA: $30.15
$46.92
52-Week Range
$11.27
Now: $46.25
$47.08
Volume696,800 shs
Average Volume631,222 shs
Market Capitalization$2.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.50 million
Book Value$4.92 per share

Profitability

Net Income$-64,940,000.00

Miscellaneous

Employees72
Market Cap$2.17 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.


Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.03. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

11 brokerages have issued twelve-month price targets for Ra Pharmaceuticals' stock. Their predictions range from $42.00 to $55.00. On average, they anticipate Ra Pharmaceuticals' share price to reach $48.20 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

News stories about RARX stock have trended extremely negative recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a coverage optimism score of -4.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Ra Pharmaceuticals.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,300,000 shares, an increase of 24.5% from the August 30th total of 2,650,000 shares. Based on an average trading volume of 464,400 shares, the days-to-cover ratio is currently 7.1 days. Currently, 8.5% of the company's stock are sold short. View Ra Pharmaceuticals' Current Options Chain.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read, Chief Scientific Officer (Age 48)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (2.61%), Rhenman & Partners Asset Management AB (0.52%), Meeder Asset Management Inc. (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which institutional investors are selling Ra Pharmaceuticals stock?

RARX stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Ra Pharmaceuticals company stock in the last year include Alonso Ricardo, Ramin Farzaneh-Far and Simon Read. View Insider Buying and Selling for Ra Pharmaceuticals.

Which institutional investors are buying Ra Pharmaceuticals stock?

RARX stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Rhenman & Partners Asset Management AB and Meeder Asset Management Inc.. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $46.25.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $2.17 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://rapharma.com/.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel